

Marleen Kok

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1937551/publications.pdf>

Version: 2024-02-01

28
papers

2,485
citations

394421

19
h-index

477307

29
g-index

29
all docs

29
docs citations

29
times ranked

3667
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer. Expert Opinion on Investigational Drugs, 2022, 31, 567-591. | 4.1 | 29 |
| 2 | Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy. Journal of Clinical Oncology, 2022, 40, 2361-2374. | 1.6 | 45 |
| 3 | LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer. Nature Cancer, 2022, 3, 355-370. | 13.2 | 21 |
| 4 | Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments. Clinical Cancer Research, 2022, 28, 960-971. | 7.0 | 4 |
| 5 | A High-Dimensional Window into the Micro-Environment of Triple Negative Breast Cancer. Cancers, 2021, 13, 316. | 3.7 | 16 |
| 6 | Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer. Nature Communications, 2021, 12, 5668. | 12.8 | 91 |
| 7 | Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group. Cancers, 2021, 13, 4910. | 3.7 | 8 |
| 8 | Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01). Breast Care, 2021, 16, 1-9. | 1.4 | 3 |
| 9 | Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers. Science Translational Medicine, 2021, 13, eabe6201. | 12.4 | 19 |
| 10 | The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. Npj Breast Cancer, 2021, 7, 150. | 5.2 | 112 |
| 11 | Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. Npj Breast Cancer, 2020, 6, 15. | 5.2 | 16 |
| 12 | Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. Npj Breast Cancer, 2020, 6, 16. | 5.2 | 90 |
| 13 | Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. Npj Breast Cancer, 2020, 6, 17. | 5.2 | 106 |
| 14 | The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. Journal of Pathology, 2020, 250, 667-684. | 4.5 | 142 |
| 15 | Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy. European Journal of Cancer, 2020, 127, 240-250. | 2.8 | 21 |
| 16 | Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nature Medicine, 2020, 26, 566-576. | 30.7 | 736 |
| 17 | The NF- κ B Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor-Positive Breast Cancers. Molecular Cancer Research, 2020, 18, 1018-1027. | 3.4 | 31 |
| 18 | Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes. Breast Cancer Research, 2019, 21, 90. | 5.0 | 81 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. <i>Nature Medicine</i> , 2019, 25, 920-928. | 30.7 | 589 |
| 20 | Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 151. | 5.0 | 30 |
| 21 | Tumor-infiltrating lymphocytes and ductal carcinoma in situ of the breast: friends or foes?. <i>Modern Pathology</i> , 2018, 31, 1012-1025. | 5.5 | 25 |
| 22 | Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, <i>BRCA1</i> -like status, tumor-infiltrating immune cells and survival. <i>Oncotarget</i> , 2018, 7, e1509820. | 4.6 | 80 |
| 23 | Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. <i>Drugs</i> , 2017, 77, 1313-1336. | 10.9 | 39 |
| 24 | Profound Immunotherapy Response in Mismatch Repair-Deficient Breast Cancer. <i>JCO Precision Oncology</i> , 2017, 1, 1-3. | 3.0 | 11 |
| 25 | Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy. <i>Oncotarget</i> , 2017, 8, 113531-113542. | 1.8 | 8 |
| 26 | Targeting the programmed cell death-1 pathway in breast and ovarian cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2016, 28, 142-147. | 2.0 | 47 |
| 27 | Protein Kinase A-induced tamoxifen resistance is mediated by anchoring protein AKAP13. <i>BMC Cancer</i> , 2015, 15, 588. | 2.6 | 24 |
| 28 | PKA-induced phosphorylation of ER α at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 1-12. | 2.5 | 49 |